7-Day Learning Paths

You can explain GMP to a non-specialist without using jargon. You understand the difference between GMP, GCP, and GLP.

Don't try to memorize CFR section numbers. Don't read the actual CFR yet, the goal today is conceptual framing.

You can define all nine ALCOA+ principles without looking them up. You can give a real example of each one failing.

Don't confuse ALCOA (five principles) with ALCOA+ (nine principles). Don't just memorize the acronym, understand what each principle is protecting against.

You understand why computerized systems need validation, not just "because FDA says so" but what specifically can go wrong without it.

Don't confuse validation with testing. Testing is part of validation but validation is a documented program, not a single activity.

You understand the difference between a deviation (something happened) and a CAPA (root cause found and prevented from recurring). You understand why weak CAPAs are a major inspection finding.

Don't confuse immediate correction with CAPA. An immediate correction fixes the symptom; CAPA fixes the system.

You can describe what happens during a typical FDA GMP inspection and what data integrity evidence an inspector requests.

Don't assume inspections are purely about paperwork. Inspectors observe behavior, ask specific questions, and request electronic data.

You can explain why each deliverable exists in the validation package and what gap it fills. You understand what a traceability matrix is and why it matters.

Don't think of validation deliverables as forms to fill out. Each one answers a specific question that an inspector or auditor would ask.

You can walk someone through the GxP quality framework in under 5 minutes without notes. You know what you still need to learn.

Don't try to cover everything. The goal is a map you can hold in your head, not a comprehensive reference document.

You can explain the GAMP 5 category system and why Category 4 systems require more documentation than Category 3. You understand how CSA relates to GAMP 5 Second Edition.

Don't treat GAMP categories as rigid boxes. The category determines the depth of validation effort, not a prescriptive document checklist.

You can describe the difference between a compliant audit trail and a cosmetic one. You know what "review by exception" means, how to design it, and what it doesn't exempt you from.

Don't assume an audit trail is compliant just because the system has one. The audit trail must be enabled, comprehensive, and regularly reviewed, and all three must be documented.

You can apply a risk-based approach to scope a validation project. You can justify why some functions require more testing and others can be documented with less evidence.

Don't conflate risk assessment with IQ/OQ/PQ. The risk assessment determines the scope and approach; the IQ/OQ/PQ executes the testing.

You understand the difference between a minor change (no re-testing), moderate change (targeted re-testing), and major change (significant re-testing). You know what impact assessment must cover.

Don't use change control as a rubber stamp. The point of change control is to determine impact, if the impact assessment is always "no impact," the process is not being applied properly.

You can identify the highest-risk points in a data lifecycle and explain why transfer steps and hybrid record creation are common failure points.

Don't focus only on the system, the people, procedures, and physical controls around the system are part of the data lifecycle.

You understand that periodic review is not just a documentation exercise, it is the mechanism that confirms validated status over time.

Don't let periodic review become a check-the-box activity. If every review concludes "validated status maintained" with no findings, it's probably not rigorous enough.

You can conduct a structured self-assessment and write findings in the same language an FDA investigator would use.

Don't write gaps in a way that minimizes them. If the gap is real, describe it accurately. You're preparing to find them before an inspector does.

You can describe the full scope of a defensible DI program, not just the technical controls. You understand that DI is a quality system element, not an IT function.

Don't design a DI program that only covers electronic systems. Paper records, hybrid systems, and backup procedures are equally in scope.

You can design and execute a gap assessment that surfaces the same findings FDA would, before they do. You can write findings in a format that supports an actionable CAPA.

Don't limit gap assessment to document review. Interview the users, observe the workflows, and compare what procedures say happens with what the audit trails show happened.

You can construct and deliver a coherent data integrity inspection narrative, not just a binder of documents, but a story that demonstrates program completeness.

Don't prepare for the questions you want to answer. Prepare for the questions you are afraid of answering.

You can write a 483 response that closes an observation rather than creating follow-up questions. You understand the difference between a response that satisfies FDA and one that generates a Warning Letter.

Don't have legal write the 483 response without quality input. Legal minimizes exposure; FDA wants to see quality understanding and systemic correction. These goals conflict.

You can design a remediation program that addresses the finding, builds sustainable controls, and generates evidence of effectiveness, not just documentation of activity.

Don't design a remediation program around fixing symptoms. Warning Letter responses that address observation wording without addressing root cause get responded to by FDA with more questions.

You understand how GxP data integrity and validation requirements connect to regulatory submission readiness. You can identify which gaps would delay or jeopardize a BLA.

Don't wait for a regulatory submission deadline to audit DI program readiness. Submissions amplify existing gaps, they don't create new ones.

You can design a DI/CSV program that a regulator would consider complete and a business leader could execute. You can explain the trade-offs between risk, resource, and timeline.

Don't design a program that requires perfect resources. Design one that is risk-prioritized and executable with a realistic team.